Variant Summary
- Also known as
- High Tumor Mutational Burden,TMB-H
- HGVS
- —
- Variant Type(s)
- —
- Evidence Items
- 11
Evidence Level Distribution
Level B: 11
Evidence Items
Showing CIViC evidence rows where gene = TMB and variant = High.
| Level | Type | Direction | Significance | Disease | Drugs | Rating |
|---|---|---|---|---|---|---|
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Durvalumab,Tremelimumab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Pembrolizumab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Solid Tumors, Advanced | Immune Checkpoint Inhibitor | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | PD1 Inhibitor,PD-L1 Inhibitor | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Atezolizumab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Solid Tumor | Pembrolizumab | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Ipilimumab/Nivolumab Regimen | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Toripalimab,Chemotherapy | 4 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Ipilimumab/Nivolumab Regimen | 3 |
| B | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Durvalumab/Tremelimumab Regimen | 3 |
| B | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Pembrolizumab | 1 |